graphic 2.png

Halucenex is a life sciences development company with a focus on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine. Halucenex operates a 6000 sqft medical facility in Windsor, Nova Scotia with 6 treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research. Halucenex intends to maintain control over all aspects of the product development process – mycological research, extraction technology, and synthetic formulation as well as drug delivery technologies, psychedelic-assisted psychotherapy and regulatory affairs.


  • cGMP Grade Psychedelic Compounds

  • Psychedelic-assisted psychotherapy treatment facility

  • Clinical trial infrastructure

  • Modern laboratory equipment

  • Genetics testing facilities

  • Finished product testing

  • Cultivation facilities

  • Extraction labs


Market Focus - Veterans


Halucenex is focused on researching psilocybin, psilocybin-derivatives and other psychedelic medicine for the purposes of treating clients suffering from PTSD and anxiety using its comprehensive psilocybin-assisted psychotherapy treatment model. Halucenex is committed to advancing the science around the use of psilocybin in psychedelic-assisted psychotherapy by:


  • researching how unique compounds present in specific mushroom strains work together to facilitate treatment;

  • performing clinical trials on psilocybin-assisted psychotherapy and microdosing on mental health; and

  •  compiling and analyzing patient experience/feedback


William (Bill) Fleming (President & CEO and Veteran)


David James PhD Chemistry (Quality Assurance)


Niall J. Buckley (Clinical Lead Physician)


Mitchel Fleming (Director)

Don Hunter (Senior Vice President Business Development and Strategic Partnerships)